轩竹生物-B(02575)：吡洛西利联合氟维司群治疗HR+/HER2-晚期乳腺癌III期临床研究最终分析结果于国际顶尖期刊《JAMA Oncology》发表

智通财经03-24

智通财经APP讯，轩竹生物-B(02575)发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利(Bireociclib)的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》(JAMA Oncology，医学1区，影响因子20.1)正式在线全文发表。BRIGHT-2研究是一项在中国开展的随机、双盲、安慰剂对照、多中心III期临床试验，旨在评估...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2621206968?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-24 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621206968","market":"sh","top_or_hot":-1,"title":"轩竹生物-B(02575)：吡洛西利联合氟维司群治疗HR+/HER2-晚期乳腺癌III期临床研究最终分析结果于国际顶尖期刊《JAMA Oncology》发表","media":"智通财经","content":"<div>\n<p>智通财经APP讯，轩竹生物-B(02575)发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利(Bireociclib)的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》(JAMA Oncology，医学1区，影响因子20.1)正式在线全文发表。BRIGHT-2研究是一项在中国开展的随机、双盲、安慰剂对照、多中心III期临床试验，旨在评估...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1418161.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>轩竹生物-B(02575)：吡洛西利联合氟维司群治疗HR+/HER2-晚期乳腺癌III期临床研究最终分析结果于国际顶尖期刊《JAMA Oncology》发表</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n轩竹生物-B(02575)：吡洛西利联合氟维司群治疗HR+/HER2-晚期乳腺癌III期临床研究最终分析结果于国际顶尖期刊《JAMA Oncology》发表\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-24 19:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1418161.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，轩竹生物-B(02575)发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利(Bireociclib)的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》(JAMA Oncology，医学1区，影响因子20.1)正式在线全文发表。BRIGHT-2研究是一项在中国开展的随机、双盲、安慰剂对照、多中心III期临床试验，旨在评估...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1418161.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4203","symbol_name":"医疗保健房地产投资信托","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1418161.html","article_id":"2621206968","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621206968","pubTimestamp":1774350738,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，轩竹生物-B 发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》正式在线全文发表。BRIGHT-2研究最终分析结果显示，吡洛西利联合氟维司群为患者带来了具有临床意义且持久稳健的获益。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4203":"医疗保健房地产投资信托","02575":"轩竹生物-B","III":"信息服务","BK4134":"信息科技咨询与其它服务","BK4225":"医疗保健房地产信托","BK1191":"制药","HR":"医疗保健房地产信托"},"translate_title":"Xuanzhu Bio-B (02575): The final analysis results of the phase III clinical study of piroxilib combined with fulvestrant in the treatment of HR + /HER2-advanced breast cancer were published in the top international journal JAMA Oncology","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1.5,"02575":1.5,"HR":1.5},"content_text":"智通财经APP讯，轩竹生物-B(02575)发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利(Bireociclib)的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》(JAMA Oncology，医学1区，影响因子20.1)正式在线全文发表。BRIGHT-2研究是一项在中国开展的随机、双盲、安慰剂对照、多中心III期临床试验，旨在评估吡洛西利联合氟维司群在既往内分泌治疗进展后的激素受体阳性( HR+)、人类表皮生长因子受体2阴 性( HER2-)( HR+/HER2-)晚期乳腺癌患者中的疗效与安全性。本研究由中国医学科学院肿瘤医院徐兵河院士牵头，在全国64家医院开展。公司曾于2025年4月在《 Nature Communications》期刊上公布BRIGHT-2研究的中期分析结果。本次发表的为最终分析结果，在中期分析的基础上增加额外11个月的观察期，中位随访时间已延长至19个月，进一步揭示了吡洛西利在生存获益上的成熟度与稳健性。BRIGHT-2研究最终分析结果显示，吡洛西利联合氟维司群为患者带来了具有临床意义且持久稳健的获益。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621206968","isCrawlerRequest":true}